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Abstract
Context: Oesophageal Cancer (OC) is an aggressive malignancy which can be temporarily managed with Self-Expanding Metal Stents (SEMS) 
to improve patient’s dysphagia and “bridge the gap” preceding surgical resection.
Aims: This study aimed to determine whether SEMS has an adverse effect on patient’s oncological outcome and mean survival time through 
a retrospective data analysis.
Methods and Material: We retrospectively analysed 121 patients with OC who underwent curative resection between 2010 to 2015 and who 
underwent SEMS insertion (stent group, n=108) or not (no stent group, n=13) prior to surgical resection. Patients were then followed up in a 
prospective data analysis to determine survival time (months) post resection. Further analysis of oncological outcomes was performed.
Statistical analysis used: Survival data was analysed using Kaplan-Meier analysis and statistical analysis included the Chi-Squared test 
(categorical data) and cox regression for hazard ratios. P < 0.05 was considered as significant.
Results: Mean survival time was considerably higher for patients in the non-stent group compared to the stent group (1380 days vs 737 days; 
p=0.05). This represented a 2-fold negative predictor factor on prognosis (hazard ratio = 2.28; p=0.042). These results were comparable to those 
receiving incomplete resections (hazard ratio= 2.32; p=0.12) (95% CI 1.208-4.68).
Conclusions: Oesophageal SEMS insertion is associated with significantly reduced mean survival time and oncological outcomes when 
utilised as a pre-operative ‘bridge to resection’.
Keywords: Oesphageal cancer, self-expanding metallic stents, survival, oncological outcomes, tumour micro-perforation.
Introduction
Research has suggested that Self Expanding Metal Stents (SEMS) 
provides enhancement to oral nutrition and relieves dysphagia in 
Oesophageal Cancer (OC). SEMS placement has become the standard 
of care for palliative management of OC to effectively alleviate patient’s 
dysphagia [1].  Recent research shows that SEMS can negatively impact 
upon patient survival and oncological outcomes when used as a bridge 
to surgical resection. It is thought SEMS insertion can cause tumour 
micro-perforations and tumour cell dissemination to worsen outcomes 
[2]. This study aims to determine whether pre-operative SEMS insertion 
for patients with resectable OC can reduce mean survival time using a 
five-year retrospective data analysis.
Subjects and Methods
We retrospectively analysed 121 patients with OC who underwent 
surgical resection between 2010 and 2015 at a single UK centre. 
The collected data included demographic parameters, details on 
the perioperative and surgical treatments, postoperative outcomes, 
histopathological analysis, and long-term outcomes. Patients were 
recruited according to a specific inclusion and exclusion criteria 
with any additional missing or inconsistent data excluded during 
recruitment stage leaving the above final sample cohort (Table 1).
Only patients with squamous or adenocarcinoma were included. 
All patients who underwent SEMS insertion were identified using a 
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prospectively compiled database and were compared to patients who 
did not undergo SEMS via retrospective analysis of a prospectively 
maintained database. Patients with T3 tumours and/or nodal disease 
received neoadjuvant chemo-radiotherapy as per national guidelines 
[3]. Neo-adjuvant chemo-radiotherapy was based upon standard 5-FU 
and platinum based drugs in conjunction with concomitant 45 Gy 
direct beam radiotherapy. Locally advanced tumours for which pre-
operative staging suggested that R0 resection would be questionable 
also received neo-adjuvant treatment. Surgical technique used was 
standard Ivor Lewis oesphagectomy in all open cases and laparoscopic 
technique in all other cases with primary anastomosis. All surgery 
was trans-hiatal and single stage. The indications for SEMS insertion 
was dysphagia for all patients. Covered SEMS were deployed in the 
standard manner over guide wires with the aid of radiologic imaging 
and endoscopic confirmation of the stent position. As the aim of the 
study was the determine the impact of SEMS on long term oncological 
outcomes, only patients who had successfully placed stents were 
included in the study and the decision process surrounding the SEMS 
placement was not considered. The pre-operative TNM classification 
was based on endoscopic ultrasound with traditional CT scanning 
methods used in cases where tumour progression prevented full 
endoscopic ultrasound examination performed before any stenting. 
This was used in conjunction with positron emission tomography 
where metastatic disease was questioned. All patients were evaluated 
by a multidisciplinary team and treated with curative intent according 
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to NICE guidelines for treatment [3]. Resection margin was considered 
R0 if completely resected, R1 if microscopically involving resection 
margins and R2 if macroscopically involving resection margins. 
All patients were followed up from December 2010 until death or 
December 2015 according to NICE guidance [3]. The primary outcome 
measure was to evaluate the impact of pre-operative SEMS insertion on 
survival time over a 5-year study period. Secondary outcome measures 
included R0 resection rate, TNM stage, age, tumour differential and 
type of operation (laparoscopic vs open) on mortality. Quantitative 
variables are expressed as the mean ± SD or the median (range). Survival 
distributions were estimated using the adjusted Kaplan-Meier method 
and compared using a log-rank test. Univariate and multivariate Cox 
proportional hazards models were used to determine hazard ratios and 
their 95% CIs. All tests were 2-sided and the threshold for statistical 
significance was set at p< 0.05. Analyses were performed with SPSS 
software, version 19.0 (SPSS, Inc).
Results
Demographic characteristics the comparison of demographic 
characteristics between the two groups (Table 2).
The median age of the patients in the stent and non-stent groups 
was 61.6 and 66.9 years, respectively (p=0.119). There was however 
a difference between the resected histological characteristic of the 
specimens. In the stent group 100% of specimens were classified at T3 
whereas only 50.3% of non-stent group was T3 with 20.4% classified 
as T2 and 23.3% shown to be T1. There was also 3.9% classified as T0. 
Stent patients tended to have a higher nodal classification with 40% 
classified as N3 (compared with 8.7% of non-stent patients). This was 
also noted in that 53.4% of non-stent patients had N0 disease. Overall 
survival is shown in (Table 3).
Tumour differentiation was however comparable between the 
two groups with the majority of tumours classified as moderately 
differentiated adenocarcinoma (stent vs non stent 61.6 and 66.9 
respectively).
Kaplan - Meier curves  a significantly different predicted survival 
between the two groups (p=0.05) (Figure 1). Table 3 shows that the 
mean survival of the non-stent group was 45.3 months (95% CI 40.6 - 
50.1) compared to 24,2 months in the stent group (95% CI 14.1 - 34.2).
Table 4 shows the differences between the oncological outcomes 
using cox regression to determine the hazard ratios for each variable.
It shows that there is over a 2-fold increase in the risk of early death 
related to the placement of stents (95% CI 1.032-5.056) (p=0.042). 
This increase in early death rates was also significantly raised in the 
incomplete resection group which again shows over a 2-fold increase 
in risk of early death (95% CI 1.208-4.68). None of the other variables 
measured showed a significant difference.
Discussion
Oesophageal cancer is an aggressive malignancy with an annual 
incidence of around 45,900 in Europe [4]. Diagnosis is often made in 
the advanced stage due to a lack of widespread screening tools, delayed 
clinical presentation and rapid disease progression. Approximately 
40-50% of patients with newly diagnosed OC are amenable to surgical 
resection which remains the gold standard for curative treatment [5]. 
Some patients continue to suffer with significant malignant dysphagia 
during the pre-operative stage of surgical resection, predisposing 
to significant; weight loss, malnutrition and reduced quality of 
life. Increasing enteral nutrition during the pre-operative stage via 
nasogastric tube or Percutaneous Endoscopic Gastrostomy (PEG) 
feeding can ensure adequate calorific intake in malnourished OC 
patients and provide an effective ‘bridge to resection’. However, these 
treatment options are associated with significant complications such 
as: displacement, aspiration pneumonia and sinusitis [6]. In addition, 
alternative methods such as operative jejunostomy and parenteral 
nutrition can be utilised to enhance calorific intake but again are 
associated with significant drawbacks such as: risk of infection, 
displacement and gut bacterial translocation [7]. Nevertheless, the 
most important disadvantage is that these methods do not alleviate 
dysphagia for patients and thus have minimal impact on improving 
quality of life. At present, SEMS insertion has become a common 
procedure to treat dysphagia for OC patient’s and improve their 
nutritional status prior to surgical resection. However, current 
European Society of Gastrointestinal Endoscopy (ESGE) guidelines 
and recent research has suggested that SEMS insertion is not only 
associated with significant complications (e.g. perforation), but also 
provides a negative prognostic impact on patient survival when utilised 
as a ‘bridge’ to surgical resection [2,3,8]. To our knowledge this is the 
first study within the United Kingdom to determine whether pre-
operative SEMS insertion for patients with resectable OC can adversely 
impact upon mean survival time and oncological outcomes using 
a retrospective data analysis at a single centre Hospital. Our results 
demonstrate that SEMS insertion has a significant negative impact 
upon oncological outcomes and survival time when inserted prior to 
surgical resection for OC patients.
Our results are comparable with other published data within the 
literature, with Mariette et al. demonstrating that SEMS insertion prior 
to surgical resection of OC produces a higher mortality and morbidity 
rate (13.2% vs 8.6% (p=0.370) and 63.2% vs 59.2% respectively 
(p=0.658) [2]. Furthermore, Kjaer et al. recently demonstrated 
compelling evidence over a longer study period on the negative impact 
of SEMS insertion on patient survival for gastroesophageal junction 
cancer (11.6 months vs 21.3 months; p<0.001) [9]. Our results, in 
conjunction with compelling evidence within the literature enable 
us to draw concrete conclusions on the inverse proportion between 
SEMS insertion and survival time. Interestingly, previous articles have 
postulated that the timing of oesophageal stent removal and surgery 
may impact upon survival. Interestingly, it is important to note that the 
paper by Mariette et al. patients had their SEMS removed immediately 
prior to surgical resection which may have increased mechanical shear 
stress and potentiate tumour cell dissemination immediately prior to 
surgical resection to negatively impact oncological outcomes [2]. To 
that end, several authors have reported that SEMS removal 4-6 weeks 
after starting neoadjuvant chemotherapy can decrease fibrosis and 
SEMS-related complications [10,11]. Although, research in relation to 
optimal SEMS removal prior to surgical resection is sparse and results 
cannot be accurately compared.
Furthermore, the negative prognostic implications of SEMS 
insertion is well recognised amongst other malignant states, namely 
colorectal cancer. Published data has shown that SEMS insertion 
Inclusion Exclusion
•	 No distant metastatic disease •	 Neo adjuvant chemo/radiotherapy
•	 No local invasion to 
unresectable structures
•	 Locally invasive or distant 
metastatic disease
•	 Oesophageal cancers only •	 WHO performance score 4/5
•	 Trail by dissection •	 Concurrent malignancy (primary)
•	 All oesophageal cancers 
treated with curative intent
Table 1: Inclusion and exclusion criteria for patients.
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Demographic data (all patients)
Total patients 121
Total stents placed 13
Trial by dissection/unresectable Stents for 7
dysplasia only 12
Demographic data (cancer patients only)
Stents (n=13 ?) No stent (n=108)
R1 5(41.7%) 21(19.4%) 0.92
Moderate dill 8(60%) 70 (64%)
Poor dill 3(20%) 36 (33.70")
Well dill 2 (20%) 2 (2.201')
(n=10, after exclus ion of trial dissections) (n=103, after exclus ion of trial dissections)
T3 10 (100%) 52 (50.5%) 0.85
T2 0 (0%) 22 (20.4%)
T1 0 (0%) 25(23.3%)
TO 0 (0%) 4 (3.9%)
nodalyield (mean) 18.7 19.1 270
N3 4 (-40%) 9(8.7%) 0.1
N2 1(16%) 16 (15.5%)
N1 3(36%) 23(22.3%)
NO 2 (20%) 55(53.4%)
Age (median) 61.6 66.9 0.12
Table 2: Demographic data for all patients and cancer patients separately.
Pre op sent




Lower Bound Upper Bound
No Stent 45.372 2.420 40.614 !i0.131
Stent 24.240 !i.127 14.190 34.290
Overall 43.450 2.336 38.870 48.029
Table 3: Mean survival times of patients with a stent and no stent 
(p=0.05).
P Value Hazard Ratio
95.0% CI for Exp(B)
Lower Upper
Stent 0.042 2 1.032 5.056
Staging (TNM) 0.686 1.029 0.898 1.179
Tumour differential 0.342 1.165 0.850 1.596
Incomplete resection 0.012 2.323 1.208 4.468
Age 0.787 1.048 0.746 1.472
Operation (lap vs 
open) 553 1.123 0.766 1.645
Table 4: Oncological outcomes hazard ratios including confidence 
intervals.
 
Figure 1: Kaplan-Meier curve showing the comparative survival 
time (months) between those who received a pre-operative stent 
(green line) compared to those who did not receive a stent (blue 
line).
when utilised as a ‘bridge’ to resection for acute left sided colorectal 
cancer can negatively impact oncological outcomes with significantly 
greater 5-year mortality (48% vs 21%, p=0.02) [12]. Several theories 
exist to explain the detrimental prognostic impact of SEMS insertion 
on survival. One of the main recognised theories suggests that during 
SEMS insertion, expansive radial forces and shearing of tumour cells 
can induce micro-perforations of cell lumens and subsequent tumour 
cell dissemination. This theory has been supported with evidence to 
suggest that higher circulating levels of CK20 mRNA after endoscopic 
stenting of obstructing colonic cancer is the result of tumour cell 
dissemination due to mechanic force imposed upon the tumours by 
the stent [13].
Baseline characteristics of the stent group demonstrate more 
advanced disease state with respect to TNM and R1 resections (Table 
2). Therefore, it is not surprising to find that the patients attributed 
to the stent group had significantly reduced mean survival time in 
comparison to those without. However, previous research has shown 
that even with closely matched baseline characteristics including TNM 
staging, SEMS insertion has a profound negative impact on patient 
survival9. We as authors speculate that TNM stage did not prove to be 
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incidence and mortality patterns in Europe: Estimates for 40 
countries in 2012. Eur J Cancer. 2013; 49:1374-1403.
5. Hirdes MM, Vieggaar FP, Siersema PD. Stent placement for 
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placement of retrievable expandable metallic stents during 
preoperative neo adjuvant chemo radiotherapy in patients with 
resectable esophageal cancer. J VascInterv Radiol. 2015; 26: 883-
888.
12. Sabbagh C, Browet F, Diouf M, et al. Is stenting as “a bridge to 
surgery” an oncologically safe strategy for the management of 
acute, left-sided, malignant, colonic obstruction? A comparative 
study with a propensity score analysis. Ann Surg. 2013; 258: 107-
115.
13. Maruthachalam K, Lash GE, Shenton BK, et al. Tumour cell 
dissemination following endoscopic stent insertion. Br J Surg. 
2007; 94: 1151-1154.
14. Min YW, Jang EY, Jung JH, et al. Comparison between gastrostomy 
feeding and self-expandable metal stent insertion for patients with 
esophageal cancer and dysphagia. PLoS One. 2017; 12: e0179522.
a predictor of worsening oncological outcomes likely due to our small 
sample size. In addition, our results indicated that SEMS insertion is 
also associated with greater R1 resections, which again can potentiate 
tumour cell dissemination and has shown within our results to 
negatively prognosticate survival time.
Baseline nutritional status has been shown to be an independent 
predictive factor for increased postoperative morbidity and 
mortality, lower rates of resectability and surviva [14]. Interestingly, 
these findings in conjunction with the novel findings of worsening 
oncological outcomes with SEMS insertion have led to researchers 
comparing alternative feeding methods to maintain nutritional status. 
The study by Won Min et al. demonstrated compelling evidence that 
PEG feeding offers significantly increased survival time (hazard ratio 
0.557; p=0.007) and greater nutritional status in comparison to SEMS 
insertion for OC when compared during the pre-operative stage of 
surgical resection [14]. Therefore, our results in conjunction with novel 
data in the literature demonstrate promising alternative methods of 
feeding during pre-operative period to provide a greater impact on 
nutritional status and more importantly increased patient survival.
This study has some limitations, mainly our small sample size that 
reduces our ability to confirm causality conclusions due to an under 
powered study. In addition, we as authors did not validate data on 
nutritional status and improvements in both dysphagia score and 
quality of life would provide prudent data in conjunction with survival 
time. However, our sample size is comparable with other studies in the 
literature and demonstrates evolving poignant data to suggest that stent 
placement can have a serious negative impact upon long term survival 
time in OC. Going forward, our recommendations would be to conduct 
a larger sample size to confirm our findings and also collect data on 
nutritional status and matched TNM staging at baseline and post 
SEMS insertion to confirm the causal relationship on survival time and 
oncological outcome. Our study supports growing evidence within the 
literature that oesophageal SEMS insertion should not be recommended 
as a clinical ‘bridge’ to surgical resection for patients with OC due to the 
significant negative impact upon oncological outcomes and survival 
time. More research is needed to further ascertain the clinical impact 
on patient survival and recovery by utilising other feeding modalities 
to enhance pre-operative nutritional status prior to surgical resection. 
As authors, we hypothesised that SEMS insertion will adversely impact 
mean survival time due to the process of stent insertion inducing shear 
stress and micro-perforations causing tumour cell migration and thus 
worsen oncological outcome.
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